Found: 93
Select item for more details and to access through your institution.
Sulfatase 2 protects hepatocellular carcinoma cells against apoptosis induced by the PI3K inhibitor LY294002 and ERK and JNK kinase inhibitors.
- Published in:
- Liver International, 2010, v. 30, n. 10, p. 1522, doi. 10.1111/j.1478-3231.2010.02336.x
- By:
- Publication type:
- Article
Lung cancer and metastasis: new opportunities and challenges.
- Published in:
- Cancer & Metastasis Reviews, 2015, v. 34, n. 2, p. 169, doi. 10.1007/s10555-015-9562-4
- By:
- Publication type:
- Article
New strategies to develop new medications for lung cancer and metastasis.
- Published in:
- Cancer & Metastasis Reviews, 2015, v. 34, n. 2, p. 265, doi. 10.1007/s10555-015-9553-5
- By:
- Publication type:
- Article
Genesis of Peace Education in an Era of Xenophobia and Terrorism: The Case of Africa.
- Published in:
- Journal of Pan African Studies, 2009, v. 2, n. 8, p. 260
- By:
- Publication type:
- Article
Phase 1 trial of navitoclax and sorafenib in patients with relapsed or refractory solid tumors with hepatocellular carcinoma expansion cohort.
- Published in:
- Investigational New Drugs, 2024, v. 42, n. 1, p. 127, doi. 10.1007/s10637-024-01420-8
- By:
- Publication type:
- Article
Phase I study of cediranib, an oral VEGFR inhibitor, in combination with selumetinib, an oral MEK inhibitor, in patients with advanced solid malignancies.
- Published in:
- Investigational New Drugs, 2022, v. 40, n. 1, p. 115, doi. 10.1007/s10637-021-01175-6
- By:
- Publication type:
- Article
A phase I study of the VEGFR kinase inhibitor vatalanib in combination with the mTOR inhibitor, everolimus, in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2020, v. 38, n. 6, p. 1755, doi. 10.1007/s10637-020-00936-z
- By:
- Publication type:
- Article
A phase II study of the orally administered negative enantiomer of gossypol (AT-101), a BH3 mimetic, in patients with advanced adrenal cortical carcinoma.
- Published in:
- Investigational New Drugs, 2019, v. 37, n. 4, p. 755, doi. 10.1007/s10637-019-00797-1
- By:
- Publication type:
- Article
A phase I study of the vascular endothelial growth factor inhibitor Vatalanib in combination with Pemetrexed disodium in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2019, v. 37, n. 4, p. 658, doi. 10.1007/s10637-018-0690-x
- By:
- Publication type:
- Article
A phase I study of the farnesyltransferase inhibitor Tipifarnib in combination with the epidermal growth factor tyrosine kinase inhibitor Erlotinib in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2019, v. 37, n. 2, p. 307, doi. 10.1007/s10637-018-0662-1
- By:
- Publication type:
- Article
A phase I dose-escalation study of TAK-733, an investigational oral MEK inhibitor, in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2017, v. 35, n. 1, p. 47, doi. 10.1007/s10637-016-0391-2
- By:
- Publication type:
- Article
A first-in-human phase I study to evaluate the MEK1/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2016, v. 34, n. 5, p. 604, doi. 10.1007/s10637-016-0374-3
- By:
- Publication type:
- Article
Phase 1b study of the oral gemcitabine 'Pro-drug' LY2334737 in combination with capecitabine in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2015, v. 33, n. 2, p. 432, doi. 10.1007/s10637-015-0207-9
- By:
- Publication type:
- Article
Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2015, v. 33, n. 1, p. 159, doi. 10.1007/s10637-014-0167-5
- By:
- Publication type:
- Article
A phase I study of the histone deacetylase (HDAC) inhibitor entinostat, in combination with sorafenib in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2015, v. 33, n. 1, p. 225, doi. 10.1007/s10637-014-0174-6
- By:
- Publication type:
- Article
Influence of Sociodemographic Factors on Treatment Decisions in Non-Small-Cell Lung Cancer.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Prospective observational comparison of clinical outcomes between african-american and caucasian patients receiving second-line treatment with pemetrexed for advanced non-small-cell lung cancer.
- Published in:
- 2013
- By:
- Publication type:
- Journal Article
Prospective Observational Comparison of Clinical Outcomes Between African-American and Caucasian Patients Receiving Second-Line Treatment With Pemetrexed for Advanced Non—Small-Cell Lung Cancer.
- Published in:
- Clinical Lung Cancer, 2013, v. 14, n. 6, p. 726, doi. 10.1016/j.cllc.2013.06.011
- By:
- Publication type:
- Article
Long-Term Safety and Tolerability of Sorafenib in Patients with Advanced Non-Small-Cell Lung Cancer: A Case-Based Review.
- Published in:
- Clinical Lung Cancer, 2011, v. 12, n. 4, p. 212, doi. 10.1016/j.cllc.2011.03.021
- By:
- Publication type:
- Article
Cooperative Group Research Efforts in Thoracic Malignancies 2009: A Review From the 10th Annual International Lung Cancer Congress.
- Published in:
- Clinical Lung Cancer, 2009, v. 10, n. 6, p. 395, doi. 10.3816/CLC.2009.n.075
- By:
- Publication type:
- Article
Cooperative Group Research Endeavors in Small-Cell Lung Cancer: Current and Future Directions.
- Published in:
- Clinical Lung Cancer, 2009, v. 10, n. 5, p. 322, doi. 10.3816/CLC.2009.n.044
- By:
- Publication type:
- Article
Challenges in the Use of Targeted Therapies in Non-Small Cell Lung Cancer.
- Published in:
- Cancer Research & Treatment, 2022, v. 54, n. 2, p. 315, doi. 10.4143/crt.2022.078
- By:
- Publication type:
- Article
Trends in Prices of Drugs Used to Treat Metastatic Non–Small Cell Lung Cancer in the US From 2015 to 2020.
- Published in:
- JAMA Network Open, 2022, v. 5, n. 1, p. e2144923, doi. 10.1001/jamanetworkopen.2021.44923
- By:
- Publication type:
- Article
Blocking oncogenic Ras signaling for cancer therapy.
- Published in:
- 2001
- By:
- Publication type:
- journal article
The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006.
- Published in:
- Oncogene, 2005, v. 24, n. 46, p. 6861, doi. 10.1038/sj.onc.1208841
- By:
- Publication type:
- Article
Molecular Characterization and Therapeutic Opportunities in KRAS Wildtype Pancreatic Ductal Adenocarcinoma.
- Published in:
- Cancers, 2024, v. 16, n. 10, p. 1861, doi. 10.3390/cancers16101861
- By:
- Publication type:
- Article
A Phase I Study of the Oral Dual-Acting Pan-PI3K/mTOR Inhibitor Bimiralisib in Patients with Advanced Solid Tumors.
- Published in:
- Cancers, 2024, v. 16, n. 6, p. 1137, doi. 10.3390/cancers16061137
- By:
- Publication type:
- Article
T-Cell Engagers in Solid Cancers—Current Landscape and Future Directions.
- Published in:
- Cancers, 2023, v. 15, n. 10, p. 2824, doi. 10.3390/cancers15102824
- By:
- Publication type:
- Article
Quality-of-Life (QOL) during Screening for Phase 1 Trial Studies in Patients with Advanced Solid Tumors and Its Impact on Risk for Serious Adverse Events.
- Published in:
- Cancers, 2017, v. 9, n. 7, p. 73, doi. 10.3390/cancers9070073
- By:
- Publication type:
- Article
Clinical Cancer Therapy: State of the Art – 2009.
- Published in:
- Clinical Cancer Update, 2009, v. 3, n. 1, p. 8, doi. 10.3816/CCR.2009.n.001
- By:
- Publication type:
- Article
Oncologists' reflections on patient rights and access to compassionate use drugs: A qualitative interview study from an academic cancer center.
- Published in:
- PLoS ONE, 2021, v. 16, n. 12, p. 1, doi. 10.1371/journal.pone.0261478
- By:
- Publication type:
- Article
Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 3, p. 510, doi. 10.1007/s10637-013-0062-5
- By:
- Publication type:
- Article
Erratum to: Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer.
- Published in:
- 2014
- By:
- Publication type:
- Erratum
Phase 1 study of sorafenib in combination with bortezomib in patients with advanced malignancies.
- Published in:
- Investigational New Drugs, 2013, v. 31, n. 5, p. 1201, doi. 10.1007/s10637-013-0004-2
- By:
- Publication type:
- Article
Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with erlotinib.
- Published in:
- Investigational New Drugs, 2013, v. 31, n. 4, p. 891, doi. 10.1007/s10637-012-9887-6
- By:
- Publication type:
- Article
A phase I trial of KX2-391, a novel non-ATP competitive substrate-pocket- directed SRC inhibitor, in patients with advanced malignancies.
- Published in:
- Investigational New Drugs, 2013, v. 31, n. 4, p. 967, doi. 10.1007/s10637-013-9929-8
- By:
- Publication type:
- Article
Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with pemetrexed in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2013, v. 31, n. 4, p. 927, doi. 10.1007/s10637-012-9900-0
- By:
- Publication type:
- Article
A systematic review of the business case for corporate social responsibility and firm performance.
- Published in:
- Corporate Social Responsibility & Environmental Management, 2020, v. 27, n. 2, p. 444, doi. 10.1002/csr.1838
- By:
- Publication type:
- Article
A phase 2 and pharmacological study of sapanisertib in patients with relapsed and/or refractory acute lymphoblastic leukemia.
- Published in:
- Cancer Medicine, 2023, v. 12, n. 23, p. 21229, doi. 10.1002/cam4.6701
- By:
- Publication type:
- Article
Survival trends among non‐small‐cell lung cancer patients over a decade: impact of initial therapy at academic centers.
- Published in:
- Cancer Medicine, 2018, v. 7, n. 10, p. 4932, doi. 10.1002/cam4.1749
- By:
- Publication type:
- Article
Survival of Black and White Patients With Stage IV Small Cell Lung Cancer.
- Published in:
- Frontiers in Oncology, 2021, v. 11, p. 1, doi. 10.3389/fonc.2021.773958
- By:
- Publication type:
- Article
Pilot Evaluation of Citalopram for the Treatment of Hot Flashes in Women with Inadequate Benefit from Venlafaxine.
- Published in:
- Journal of Palliative Medicine, 2005, v. 8, n. 5, p. 924, doi. 10.1089/jpm.2005.8.924
- By:
- Publication type:
- Article
A phase I study of the anaplastic lymphoma kinase inhibitor ceritinib in combination with gemcitabine‐based chemotherapy in patients with advanced solid tumors.
- Published in:
- International Journal of Cancer, 2021, v. 149, n. 12, p. 2063, doi. 10.1002/ijc.33754
- By:
- Publication type:
- Article
In the clinic: ongoing clinical trials evaluating c-MET-inhibiting drugs.
- Published in:
- Therapeutic Advances in Medical Oncology, 2011, v. 3, n. 1, p. S37, doi. 10.1177/1758834011423403
- By:
- Publication type:
- Article
A Phase 2 Study of Gemcitabine and Epirubicin for the Treatment of Pleural Mesothelioma.
- Published in:
- Cancer (0008543X), 2008, v. 112, n. 8, p. 1772, doi. 10.1002/cncr.23313
- By:
- Publication type:
- Article
The value of combined‐modality therapy in elderly patients with stage III nonsmall cell lung cancer.
- Published in:
- Cancer (0008543X), 2007, v. 110, n. 2, p. 363
- By:
- Publication type:
- Article
A prognostic model for advanced stage nonsmall cell lung cancer.
- Published in:
- Cancer (0008543X), 2006, v. 107, n. 4, p. 781, doi. 10.1002/cncr.22049
- By:
- Publication type:
- Article
A phase II study of bortezomib in the treatment of metastatic malignant melanoma.
- Published in:
- Cancer (0008543X), 2005, v. 103, n. 12, p. 2584
- By:
- Publication type:
- Article
Results of combined‐modality therapy for limited‐stage small cell lung carcinoma in the elderlyAdditional participating institutions include the following: Duluth CCOP, Duluth, MN (Daniel A. Nikcevich, M.D.); Cedar Rapids Oncology Project CCOP, Cedar Rapids, IA (Martin Wiesenfeld, M.D.); Meritcare Hospital CCOP, Fargo, ND (Ralph Levitt, M.D.); Toledo Community Hospital Oncology Program CCOP, Toledo, OH (Paul L. Schaefer, M.D.); Sioux Community Cancer Consortium, Sioux Falls, SD (Loren K. Tschetter, M.D.); Geisinger Clinical Oncology Program, Danville, PA (Suresh Nair, M.D.); Rapid City Regional Oncology Group, Rapid City, SD (Larry P. Ebbert, M.D.); Saskatoon Cancer Center, Saskatoon, Saskatchewan, Canada and Allan Blair Cancer Centre, Regina, Saskatchewan, Canada (Muhammad Salim, M.D.); Scottsdale CCOP, Scottsdale, AZ (Tom R. Fitch, M.D.); Carle Cancer Center CCOP, Urbana, IL (Kendrith M. Rowland, M.D.); Medcenter One Health Systems, Bismarck, ND (Ferdinand Addo, M.D.); Altru Health S
- Published in:
- Cancer (0008543X), 2005, v. 103, n. 11, p. 2349, doi. 10.1002/cncr.21034
- By:
- Publication type:
- Article
Tumor Mutational Burden From Tumor-Only Sequencing Compared With Germline Subtraction From Paired Tumor and Normal Specimens.
- Published in:
- JAMA Network Open, 2020, p. e200202, doi. 10.1001/jamanetworkopen.2020.0202
- By:
- Publication type:
- Article